Stanley, Isabelle Kitty, Mallett, Andrew J., Viecelli, Andrea K., Hawley, Carmel M., Staatz, Christine E., Johnson, David W., and Milanzi, Elasma (2024) A Post Hoc Analysis of the CKD-FIX Study Analyzing the Association Between Metformin Usage and Estimated GFR Decline. Kidney International Reports, 9. pp. 1525-1527.

Preview

PDF (Published Version) - Published Version Available under License Creative Commons Attribution. Download (271kB) | Preview

Abstract

[Extract] Chronic kidney disease (CKD) poses an increasing burden on global health; however, there are few interventions available to manage the condition. It has been hypothesized that metformin, a commonly prescribed oral antidiabetic drug, may potentially be able to slow the progression of CKD.1 Metformin is the first line treatment for patients with type 2 diabetes mellitus (T2DM) due to its beneficial effects on blood glucose control and its tolerability.1 It primarily imparts its therapeutic actions through activation of adenosine monophosphate-activated protein kinase, which subsequently inactivates the molecular target of rapamycin and its postulated downstream fibrogenic effects on the kidney.1 Metformin therapy may therefore improve outcomes in CKD in addition to the benefits of improved blood glucose control.

Item ID:	85879
Item Type:	Article (Research - C1)
ISSN:	2468-0249
Copyright Information:	© 2024 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license http://creativecommons.org/licenses/by/4.0/
Date Deposited:	18 Jun 2025 00:24
FoR Codes:	32 BIOMEDICAL AND CLINICAL SCIENCES > 3202 Clinical sciences > 320214 Nephrology and urology @ 100%
SEO Codes:	20 HEALTH > 2001 Clinical health > 200105 Treatment of human diseases and conditions @ 100%
	More Statistics